Pinetree Therapeutics, Inc., a Cambridge, MA-based biotechnology company advancing next-generation targeted protein degraders (TPD) to combat drug resistance in oncology and beyond, raised $17m in Series A funding round.
The round was co-led by STIC Investments and DSC Investment. New investors including Atinum Investment, Quantum FA, and S&S Investment, joined existing investors DSC Investment, Schmidt, and SGI Partners.
The company intends to use the funds to leverage its AbReptor™ antibody degrader platform to advance its novel multispecific TPD development programs across multiple tumor types and targets in several oncology indications, with potential application in other therapeutic areas.
Led by Dr. Hojuhn Song, Founder and CEO, Pinetree leverages AbReptor™, a versatile antibody-based TPD platform that functions through co-engaging a surface-receptor or extracellular protein of interest together with another proprietary receptor target to advance multiple preclinical candidates derived from its AbReptor™ TPD platform with potential in oncology and other therapeutics areas, including candidate degraders indicated for TKI-resistant tumors, immune checkpoint inhibitor-resistant tumors, and other disease targets.
FinSMEs
30/07/2024